Panacea Biotec Pharma Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Panacea Biotec Pharma Limited Pharmaceutical Export Portfolio Dataset — 13 Products, $23.9M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Panacea Biotec Pharma Limited — Pharmaceutical Exporter Profile (2026) | 13 Products, $23.9M Trade | TransData Nexus

Panacea Biotec Pharma Limited

Indian Pharmaceutical Exporter · Immunosuppressants Specialist · $23.9M Total Trade · DGFT Verified

Panacea Biotec Pharma Limited is an Indian pharmaceutical exporter with a total trade value of $23.9M across 13 products in 9 therapeutic categories. Based on 580 verified export shipments from Indian Customs (DGFT) records, Panacea Biotec Pharma Limited is the #1 Indian exporter in 3 products including Protein, Glucosamine, Chondroitin. Top exports include Tacrolimus ($5.2M), Paclitaxel ($3.3M), Protein ($3.0M).

Panacea Biotec Pharma Limited — Export Portfolio & Destination Treemap

Panacea Biotec Pharma Limited pharmaceutical export portfolio — 13 products across 9 therapeutic categories. Source: Indian Customs (DGFT).

Who is Panacea Biotec Pharma Limited? — Company Overview & Market Position

Panacea Biotec Pharma Limited, established in 1984 as Panacea Drugs Private Limited, is a prominent Indian pharmaceutical company specializing in the research, development, manufacturing, and marketing of pharmaceutical formulations, vaccines, biosimilars, and natural products. The company is headquartered in New Delhi, India, with additional offices in Mumbai and Lalru (near Chandigarh). Incorporated as a public limited company on 22 March 2019, it operates under the Corporate Identification Number (CIN) U24299DL2019PLC347566. As of 2025, Panacea Biotec reported a revenue of approximately $66.8 million, reflecting a 21.6% increase from the previous year. The company employs around 1,290 individuals, underscoring its significant presence in the pharmaceutical sector. For more information, visit their official website at www.panaceabiotec.com.

What Does Panacea Biotec Pharma Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Tacrolimus$5.2M 2Paclitaxel

Product Portfolio — Top 13 by Export Value

Panacea Biotec Pharma Limited exports 13 pharmaceutical products across 9 therapeutic categories. Market leader (#1 exporter) in 3 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Tacrolimus	Immunosuppressants	$5.2M	103	2.6%	5
2	Paclitaxel	Oncology	$3.3M	65	3.9%	5
3	Protein	Nutritional Supplements	$3.0M	60	20.2%	1
4	Gliclazide	Advanced Diabetes Medications	$2.5M	50	0.8%	2
5	Glucosamine	Nutritional Supplements	$1.8M	41	13.9%	1
6	Mycophenolate	Immunosuppressants	$1.8M	35	0.5%	7
7	Cyclosporine	Immunosuppressants	$1.7M	36	13.7%	3
8	Calcium	Vitamins & Supplements	$1.3M	26	0.1%	15
9	Lactulose	Gastrointestinal	$1.2M	47	9.0%	3
10	Chondroitin	Nutritional Supplements	$800.0K	16	15.7%	1
11	Extract	Ayurvedic & Herbal Products	$723.4K	72	6.0%	4
12	Dextromethorphan	Respiratory & OTC	$550.0K	11	3.7%	4
13	Ornidazole	Advanced Antibiotics	$181.0K	18	1.0%	13

Panacea Biotec Pharma Limited exports 13 pharmaceutical products across 9 therapeutic categories with a total export value of $23.9M. The company is the #1 Indian exporter in 3 products: Protein, Glucosamine, Chondroitin. The top category is Immunosuppressants (35.8% of portfolio), followed by Nutritional Supplements (23.6%), indicating a concentrated portfolio with the top 5 products accounting for 65.8% of total export value.

Panacea Biotec Pharma Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Panacea Biotec operates state-of-the-art manufacturing facilities in Baddi (Himachal Pradesh), Lalru (Punjab), and Delhi. These plants are equipped to produce a diverse range of pharmaceutical products, including tablets, capsules, syrups, injections, and vaccines. The Baddi facility is particularly notable for its capacity to manufacture vaccines, while the Lalru plant specializes in the production of pharmaceutical formulations. These facilities adhere to stringent quality standards, ensuring the production of high-quality pharmaceutical products for both domestic and international markets.

3Key Leadership

The leadership team at Panacea Biotec comprises several key executives:

Dr. Rajesh Jain: Chairman and Managing Director, responsible for overseeing the company's strategic direction and overall operations.

Sandeep Jain: Joint Managing Director and Executive Director, playing a pivotal role in the company's management and decision-making processes.

Vinod Goel: Group Chief Financial Officer and Head of Legal and Corporate Governance, overseeing financial strategies and ensuring compliance with legal and corporate governance standards.

Dr. Khalid Al Syed: Chief Scientific Officer, leading the company's research and development initiatives to drive innovation in pharmaceutical products.

Gurinder Pal Singh: Senior Vice President of Sales, responsible for driving sales strategies and expanding the company's market presence.

Dr. Sanjay Trehan: Director of Technical and Compliance and Whole-Time Director, ensuring technical excellence and regulatory compliance in the company's operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Panacea Biotec Pharma Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Panacea Biotec has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained approvals for several of its pharmaceutical formulations and vaccines from regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. Notably, Panacea Biotec has developed and marketed vaccines like EasyFive-TT, which regained World Health Organization (WHO) prequalification in September 2013 after addressing quality management issues. The company's commitment to quality and regulatory compliance has facilitated its entry and sustained presence in these markets.

2Emerging Markets

Panacea Biotec has strategically expanded its footprint in emerging markets across Africa, Latin America, and Southeast Asia. The company's products, including vaccines and pharmaceutical formulations, have been prequalified by the World Health Organization (WHO), enabling access to these regions. Collaborations with organizations like the Indian Council of Medical Research (ICMR) for clinical trials, such as those for the DengiAll vaccine, have further bolstered its presence in these markets. This strategic approach underscores Panacea Biotec's commitment to global health initiatives and its ability to navigate diverse regulatory landscapes.

Panacea Biotec Pharma Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Panacea Biotec has made notable strides in the U.S. market, with several of its pharmaceutical formulations and vaccines approved by the U.S. Food and Drug Administration (FDA). The company's manufacturing facilities are registered with the FDA, ensuring compliance with stringent quality standards. Additionally, Panacea Biotec has filed Abbreviated New Drug Applications (ANDAs) and Drug Master Files (DMFs) for various products, facilitating market entry and expansion. The company's commitment to quality and regulatory compliance is evident in its successful inspections and approvals, reinforcing its position in the U.S. market.

2WHO & EU GMP

Panacea Biotec's commitment to quality is demonstrated by its WHO prequalification for vaccines like EasyFive-TT, which regained prequalification in September 2013 after addressing quality management issues. The company's manufacturing facilities adhere to Good Manufacturing Practice (GMP) standards, ensuring the production of high-quality pharmaceutical products. These certifications and standards underscore Panacea Biotec's dedication to maintaining excellence in manufacturing processes.

3CDSCO & Indian Regulatory

Panacea Biotec Pharma Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Panacea Biotec operates in a competitive landscape with several key players in the pharmaceutical and vaccine manufacturing sectors. Competitors include companies like Zydus Lifesciences Ltd, Lupin Ltd, and GlaxoSmithKline Pharmaceuticals Ltd. Panacea Biotec differentiates itself through its focus on innovative products, such as the world's first fully liquid Pentavalent vaccine, EasyFive, launched in 2005. The company's strategic partnerships, like the collaboration with the Russian Direct Investment Fund to produce the Sputnik V COVID-19 vaccine in India, further enhance its competitive position.

2Key Differentiators

Panacea Biotec's key differentiators include its strong research and development capabilities, leading to the development of innovative products like the fully liquid Pentavalent vaccine, EasyFive. The company's strategic collaborations, such as the partnership with the Russian Direct Investment Fund for the Sputnik V COVID-19 vaccine, demonstrate its ability to engage in significant global health initiatives. Additionally, Panacea Biotec's adherence to stringent quality standards and regulatory compliance across multiple markets underscores its commitment to excellence.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Panacea Biotec Pharma Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Panacea Biotec has a commendable track record in the pharmaceutical industry, with a diverse product portfolio and a significant presence in both domestic and international markets. The company's export volume and consistency

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Panacea Biotec Pharma Limited

How many pharmaceutical products does Panacea Biotec Pharma Limited export from India?

Panacea Biotec Pharma Limited exports 13 pharmaceutical products across 9 therapeutic categories. The top exports are Tacrolimus ($5.2M), Paclitaxel ($3.3M), Protein ($3.0M), Gliclazide ($2.5M), Glucosamine ($1.8M). Total export value is $23.9M.

What is Panacea Biotec Pharma Limited's total pharmaceutical export value?

Panacea Biotec Pharma Limited's total pharmaceutical export value is $23.9M, based on 580 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Panacea Biotec Pharma Limited the #1 Indian exporter?

Panacea Biotec Pharma Limited is the #1 Indian exporter in 3 products: Protein (20.2% market share), Glucosamine (13.9% market share), Chondroitin (15.7% market share).

What therapeutic categories does Panacea Biotec Pharma Limited cover?

Panacea Biotec Pharma Limited exports across 9 therapeutic categories. The largest are Immunosuppressants (35.8%, 3 products), Nutritional Supplements (23.6%, 3 products), Oncology (13.6%, 1 products).

Get Full Panacea Biotec Pharma Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.